Drug Discov Ther. 2020;14(5):256-258. (DOI: 10.5582/ddt.2020.03070)

Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?

Adil MS, Narayanan SP, Somanath PR


In the ongoing coronavirus diseases-2019 (COVID-19) crisis that caused immense suffering and deaths, the choice of therapy for the prevention and life-saving conditions must be based on sound scientific evidence. Uncertainty and apprehension are exacerbated in people using angiotensinconverting enzyme (ACE) inhibitors to control their comorbidities such as hypertension and diabetes. These drugs are reported to result in unfavorable outcome as they tend to increase the levels of ACE2 which mediates the entry of SARS-CoV-2. Amiloride, a prototypic inhibitor of epithelial sodium channels (ENaC) can be an ideal candidate for COVID-19 patients, given its ACE reducing and cytosolic pH increasing effects. Moreover, its potassium-sparing and anti-epileptic activities make it a promising alternative or a combinatorial agent.

KEYWORDS: ACE2, ACE inhibitors, amiloride, COVID-19, cytosolic pH, ENaC

Full Text: